GEN Exclusives

More »

Feature Articles

More »
Dec 1, 2010 (Vol. 30, No. 21)

Adoption of Label-Free Technologies Surges

Methodologies Like SPR and ITC Are Saving Researchers Time and Money

  • Safer Delivery

    John McVey, Ph.D., head of experimental and translational research at the Thrombosis Research Institute, showed how using SPR data has helped in re-designing an adenovirus vector. According to Dr. McVey, the adenovirus is the most commonly used vector in gene-therapy trials, yet very little is known about its physiology. The majority of the vector is transferred into the liver, which can lead to toxicity problems, and it is this lack of understanding that led Dr. McVey and his team to study the virus.

    Dr. McVey presented SPR data showing how a blood coagulation factor (FX) binds to the hexon on the virus surface and using electron cryomicroscopy they demonstrated the FX bound to hypervariable regions (HVRs) in the hexon protein. A series of recombinant adenovirus vectors was engineered in which the HVRs were swapped and using SPR these vectors were shown not to bind to FX. The recombinant vectors were further altered by site-directed mutagenesis in the HVRs, and using SPR the amino acids in the HVRs that bound to FX were identified.

    “Using SPR we now understand a little more about how the virus could be binding to hepatocytes, we could generate new types of adenovirus, which can bypass the liver. This means we may be able to improve the safety profile of gene therapies using these new kinds of vector.”

  • The Future

    Delegates and speakers at the DiPIA meeting agreed that the use of label-free approaches is now more frequent in discovery of biotherapies and vaccines. However, techniques such as SPR have also shown promise in improving many downstream analytical tests, including ADME/Tox screening, bioprocessing, and QC applications.

    According to Dr. Maasch, Noxxon plans “to use SPR later in development work such as pharmacokinetic analysis using an anti-PEG antibody to track Spiegelmers. As Spiegelmers are pegylated, this will require less assay development time if we use SPR.”

    Many academic groups have been able to link bioreactors to SPR methods to provide real-time analysis of mAb production and this could be used in pharmaceutical manufacturing.

    “To ensure that Biacore instruments could make the transition from being analytical lab machines to being used in a GMP environment, we have a clear link between paper and electronic records. We also have trained personnel that will help to document everything—because the FDA’s view is unless it’s documented it never happened. SPR assays are already being used in batch-release applications by some biopharma companies. We expect that over the next few years other companies will follow and start implementation of label-free assays in this key area,” Sundberg said.

    SPR assays are already being used in batch-release applications by some biopharma companies. We expect that over the next few years other companies will follow and start implementation of label-free assays in this key area,” Sundberg added.

    In short, label-free technologies are going from strong to stronger in the development and manufacture of biotherapies and vaccines. “When the pharmas and biotechs start trying to gain approval for their biosimilar products, multiple independent technologies such as SPR, ITC, ELISA, and LC/MS, will provide a sea of protein data.

    “If the biosimilar is very well characterized and its protein profile compares well with the existing antibody or protein therapy, then regulatory authorities may allow the company to perform smaller numbers of clinical trials to get their biotherapeutics to market. This could significantly reduce the clinical development costs of the therapy and is a good reason to characterize a biosimilar very thoroughly,” Sundberg concluded.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »